Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. 1993

P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
Isis Pharmaceuticals, Inc., Carlsbad, California.

5'-TTGCTTCCATCTTCCTCGTC-3' (ISIS 2105) is a phosphorothioate oligodeoxynucleotide currently being evaluated as an intralesional antiviral drug for the treatment of genital warts that are caused by the human papillomavirus. ISIS 2105, labeled with 14C (at the carbon-2 position of thymine) was administered as a single i.v. injection (3.6 mg/kg) to female Sprague-Dawley rats to assess the disposition of the drug. After i.v. administration of [14C]2105, blood radioactivity disappeared in a multiexponential manner with the half-lives of the phases equal to 0.4, 1.9, 7.1 and 5.1 hr. The initial volume of distribution was 22 ml and the postdistribution volume of distribution was 1076 ml, which indicated an extensive distribution of radioactivity. The apparent blood clearance was 14.7 ml/hr. The radioactivity in the expired air accounted for 51% of the administered dose over the 10-day period. Urinary and fecal radioactivity accounted for 15% and 5% of the administered dose, respectively. The major sites of radioactivity uptake were the liver (up to 22.6% of the dose), kidneys (renal cortex, up to 14% of the dose), bone marrow (up to 14% of the dose), skin (up to 13% of the dose) and skeletal muscle (up to 9% of the dose). Other tissues contained approximately 1% or less of the dose. The overall recovery of radioactivity 10 days postdosing was 95.1 +/- 7.5% (mean +/- S.D.) of the administered single dose. The radioactivity in the blood was almost completely in the plasma during the course of the study. In the plasma, the radioactivity was extensively bound to proteins, as assessed by size-exclusion high-performance liquid chromatography (HPLC), in samples up to 8 hr postdosing. Retention data on size-exclusion HPLC and in vitro incubations using purified proteins suggested that the plasma proteins that bound [14C]2105 were albumin and alpha 2-macroglobulin. The complex formed between the plasma proteins and [14C]2105-derived radioactivity was dissociated on anion-exchange HPLC to indicate that the great majority of plasma radioactivity coeluted with intact [14C]2105 in samples that contained sufficient radioactivity for analysis. There was a time-dependent decrease in the proportion of hepatic and renal radioactivity that coeluted with the intact [14C]2105 during the course of the study. The urine did not contain radioactivity that eluted with intact [14C]2105 on anion-exchange HPLC.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013873 Thionucleotides Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
April 1994, The Journal of pharmacology and experimental therapeutics,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
January 1997, Toxicology,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
June 1999, Drug metabolism and disposition: the biological fate of chemicals,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
January 1998, Clinical therapeutics,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
January 2017, Drug metabolism letters,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
August 1996, The Journal of pharmacology and experimental therapeutics,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
January 1991, Drug metabolism and disposition: the biological fate of chemicals,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
November 1988, Toxicology and applied pharmacology,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
January 1985, Drug metabolism and disposition: the biological fate of chemicals,
P A Cossum, and H Sasmor, and D Dellinger, and L Truong, and L Cummins, and S R Owens, and P M Markham, and J P Shea, and S Crooke
December 1998, Antisense & nucleic acid drug development,
Copied contents to your clipboard!